Global Markets
Novo Nordisk (NOVOB DC) says investigational cagrisema 2.4 mg/2.4 mg showed 25% average weight loss in women in redefine 1 post hoc analysis
StockNow breaking-news AI analysis
Novo Nordisk reported 25% average weight loss in women for investigational CagriSema 2.4 mg/2.4 mg in a REDEFINE 1 post hoc analysis; further details were not supplied.
Related stocks
1 stocks
What do investors think?
Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactionsStockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.